CTOs on the Move

Health Weeks

www.healthweeks.com

 
Health Weeks is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

EyeCare Services Partners

EyeCare Services Partners (ESP) provides ownership and practice management of ophthalmologic, optometric and ambulatory surgery centers nationwide. ESP offers eye care providers and ambulatory surgery center owners compelling and effective solutions for today`s constantly changing healthcare environment. Utilization of our resources and expertise eliminates the stress of practice management. We are creating the nation`s leading eyecare services company in both quality and scale by consolidating ophthalmologic and optometric practices and ambulatory surgery centers that are locally dominant and clinically differentiated. We provide a patient centric model that delivers outstanding care and quality outcomes through our providers and staff by leveraging our comprehensive array of best-in-class technology, processes and managerial infrastructure.

Devereux

Devereux Advanced Behavioral Health is one of the largest and most advanced behavioral healthcare organizations in the country. Informed by the latest advancements in science and medicine, we combine evidence-based interventions with compassionate family engagement to help change lives. We were founded in 1912 by special education pioneer, Helena Devereux. Today, Devereux is a national nonprofit partner for individuals, families, schools and communities, serving many of the most vulnerable members of our society in areas of autism, intellectual and developmental disabilities, specialty mental health, and child welfare. Our Mission: Devereux Advanced Behavioral Health changes lives – by unlocking and nurturing human potential in people living with emotional, behavioral or cognitive differences. Devereux Advanced Behavioral Health employs more than 7,500 staff and operates 15 centers in 13 states. We offer a comprehensive national network of clinical, therapeutic, educational, and employment programs and services that positively impact the lives of tens of thousands of children, adults – and their families – every year. Our Culture, Our Expectations At Devereux, we strive to incorporate servant leadership into our culture and every aspect of our organizational framework; from the delivery of quality services to individuals served, their families, and other stakeholders to the development and empowerment of our employees. We offer challenging and exciting work, and our supportive team environment creates an empowering and positive atmosphere. To be successful in our work environment, you will put the needs of others first, and will feel called to serve, and called to lead.

Simonmed Imaging

SimonMed Imaging is one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States. Our practice consists of over 200 highly-experienced subspecialty-trained radiologists, and we operate across 9 states with over 150 accredited facilities that are ACR-RADSITE certified with certified technologists and equipment. We specialize in using the newest diagnostic imaging technologies and bringing them to the community in an affordable and accessible way. Our logo See Tomorrow Today recognizes that new technology can help provide a more accurate diagnosis but needs to be readily available and affordable.

East Texas Council on Alcoholism

East Texas Council on Alcoholism is a Longview, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plasmatech Biopharmaceuticals

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.